Arlington Trust’s Novavax NVAX Stock Holding History

Arlington Trust’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-145	Closed	-$696	–	762
2023 Q4	$696	Buy	+145	New	+$888	﹤0.01%	868

Other funds holding NVAX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Arlington Trust's NVAX Position: Q1 2024 in Review

Arlington Trust sold out of Novavax (NVAX) in Q1 2024, closing a stake of 145 shares — an estimated $696 sold.

Arlington Trust first reported a position in NVAX in Q4 2023 and held it in 1 quarter. The position peaked at $696 in Q4 2023. 201 funds tracked by Wall St. Rank hold NVAX as of Q1 2024.

Arlington Trust reported no remaining Novavax position as of Q1 2024 after selling out during the quarter.
Arlington Trust sold 145 Novavax shares in Q1 2024, an estimated $696.
Arlington Trust first reported a position in Novavax in Q4 2023 and held it in 1 quarter.
Arlington Trust's Novavax position peaked at $696 in Q4 2023.
201 funds tracked by Wall St. Rank held Novavax as of Q1 2024.

Based on Arlington Trust's 13F filing for Q1 2024, filed 16 Apr 2024.